The CABB Group aims to help specialty chemicals companies bring innovative molecules more quickly to market. ChemSpec Europe will see the launch of a service model in which CABB will carry out all the steps required to put a customer’s molecular structure into commercial production.
These include, as required, developing a suitable synthesis process, scale-up from pilot to commercial-scale manufacturing including all aspects of safety, establishing and managing the supply chain, and further ongoing process optimization. This will provide innovators with a transparent basis for decision-making in terms of processes, resources, timeline and costs.
“Our approach provides customers with direct access to the skills, manufacturing assets, infrastructure and personnel resources they need, without requiring them to familiarize themselves with new technologies or make significant capital expenditure”, explains Thomas Eizenhöfer, Head of the Custom Manufacturing Business Unit at CABB. “On the basis of their own IP, customers will receive the finished molecule at the desired time and in the agreed volume and quality for the further processing in-house.”
CABB has brought together a team to provide this new service which combines custom manufacturing expertise with a deep understanding of the specialty chemicals industry. It also draws on the experience of affiliate company Jayhawk Fine Chemicals in Kansas, USA, which CABB’s owner Permira has recently acquired. Close collaboration between the companies gives international customers access to a production facility in the United States in addition to CABB’s manufacturing assets in Switzerland and Finland.